Research programme: allogenic stem cell therapies - SanBio

Drug Profile

Research programme: allogenic stem cell therapies - SanBio

Alternative Names: SB 308; SB 618

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SanBio
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Muscular dystrophies; Peripheral nerve injuries
  • No development reported Multiple sclerosis; Spinal cord injuries

Most Recent Events

  • 28 Feb 2018 Preclinical development in Muscular-dystrophies is ongoing in USA (Injection) (SanBio pipeline,February 2018)
  • 28 Feb 2018 Preclinical trials in Peripheral nerve injuries in USA (unspecified route) before February 2018 (SanBio pipeline, February 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top